Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Exclusion Criteria

• •1. Presence of - clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.
• •2. poor-controlled hypertension.
• •3. PHQ-9 score ≥15.
• •4. Medical history of illness that affects weight.
• •5. History of diabetes.
• •6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening.
• •7. History of acute cardiovascular and cerebrovascular diseases.
• •8. Any organ-system malignancies developed within 5 years except cured local basal cell carcinoma of skin and cervical carcinoma in situ.
• •9. Confirmed or suspected depression, bipolar disorder, suicidal tendency, schizophrenia, or other serious mental illness.
• •10. History of alcohol , medication or drug abuse within 1 year prior to screening.
• •11. Use of any medication or treatment that may cause significant weight change within 3 months.
• •12. History of bariatric surgery.
• •13. Subjects participating in QT/QTc studies need to comply with relevant examinations.
• •14. Known or suspected hypersensitivity to trial product(s) or related products.
• •15. Participation in other clinical trials within 3 month prior to screening.
• •16. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening
• •17. Surgery is planned during the trial.
• •18. Mentally incapacitated or speech-impaired.
• •19. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method.
• •20. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.
• •21. In the judgment of the investigator, there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.